Dasatinib Monohydrate

Name: Dasatinib Monohydrate
Brand: Selleck Chemicals
SKU: S7782
Rating: 5 (117 reviews)

For research use only.

Catalog No.S7782 Synonyms: BMS-354825 Monohydrate

117 publications

Dasatinib Monohydrate Chemical Structure

CAS No. 863127-77-9

Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

Selleck's Dasatinib Monohydrate has been cited by 117 publications

Science, 2020, 370(6513)eabc2754

PubMed: 33004676 ( click the link to review the publication )

Nature, 2016, 534(7607):341-6

PubMed: 27281222 ( click the link to review the publication )

Cell, 2012, 21;151(7):1457-73.

PubMed: 23245941 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Blood, 2020, 8 pii: blood

PubMed: 32270193 ( click the link to review the publication )

Leukemia, 2020, 14

PubMed: 32409689 ( click the link to review the publication )

Neuro Oncol, 2020, 15;22(4):493-504

PubMed: 31883012 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Biomaterials, 2020, 30;251:120077

PubMed: 32388166 ( click the link to review the publication )

Cell Rep, 2020, 24;30(12):3951-3963 e4

PubMed: 32209458 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):80

PubMed: 32552902 ( click the link to review the publication )

Oncogene, 2020, 39(20):4045-4060

PubMed: 32214198 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2586

PubMed: 32927828 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 25;12(5)

PubMed: 32344828 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Breast Cancer Res, 2020, 15;22(1):37

PubMed: 32295603 ( click the link to review the publication )

Cell Death Discov, 2020, 15;6:36

PubMed: 32435511 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Microb Cell Fact, 2020, 20;19(1):74

PubMed: 32197603 ( click the link to review the publication )

Biochem Pharmacol, 2020, 30;177:113941

PubMed: 32240650 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )
Breast Cancer Res Treat, 2020, 179(2):337-347

PubMed: 31655920 ( click the link to review the publication )

Molecules, 2020, 8;25(9) pii: E2220

PubMed: 32397330 ( click the link to review the publication )

Biomol Ther (Seoul), 2020, 9

PubMed: 32268657 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):84

PubMed: 32771039 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):145-154

PubMed: 32565942 ( click the link to review the publication )

J Clin Invest, 2020, 133310

PubMed: 32603316 ( click the link to review the publication )

Front Microbiol, 2020, 10:2936

PubMed: 32038511 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3416

PubMed: 32651372 ( click the link to review the publication )

Cells, 2020, 9(8):E1807

PubMed: 32751526 ( click the link to review the publication )

Cell Death Dis, 2019,

PubMed: 30988279 ( click the link to review the publication )

Nanomaterials (Basel), 2019, 9(9)

PubMed: 31461998 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Blood, 2018, 131(14):1532-1544

PubMed: 29437554 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2590

PubMed: 29968724 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):130

PubMed: 30359299 ( click the link to review the publication )

J Immunol, 2018,

PubMed: 29351998 ( click the link to review the publication )

Apoptosis, 2018, 23(5-6):343-355

PubMed: 29740790 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 502(1):110-115

PubMed: 29787755 ( click the link to review the publication )

Cell Biol Int, 2018,

PubMed: 29885023 ( click the link to review the publication )

Cancer Res, 2017,

PubMed: 27821486 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28830985 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28638122 ( click the link to review the publication )
PLoS ONE, 2017,

PubMed: 28945796 ( click the link to review the publication )

Exp Ther Med, 2017,

PubMed: 28810597 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28977994 ( click the link to review the publication )

EMBO Mol Med, 2016, 1;8(2):105-16

PubMed: 26758680 ( click the link to review the publication )

Mol Cell Endocrinol, 2016, 433:94-104

PubMed: 27267669 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27602951 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27756880 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27687593 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26623721 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )

Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

Exp Hematol, 2015,

PubMed: 25641047 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )
Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2014,

PubMed: 23318431 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

Cell Cycle, 2014,

PubMed: 24196445 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107367

PubMed: 25198091 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10(11):2876-88

PubMed: 25099472 ( click the link to review the publication )

Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )
Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(4):762-70

PubMed: 21106726 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )

Biochem Pharmacol, 2011, 82(10):1457-66

PubMed: 21664897 ( click the link to review the publication )

Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )

Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description

Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

Targets

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. ^[1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. ^[3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. ^[4]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
K562 cell	NGDq[2NRem:uaX\ldoF1cW:wIHHzd4F6	NHuxd5o4OiCq	NWf3eZFWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IEeyJIhzeyxiSVO1NF0xNjByMTFOwG0>	MWexOVYyPTVzMh?=
WiDr cell	M4LhUXBzd2yrZnXyZZRqd25iYYPzZZk>	NHzmN\|g4OiCq	Ml73RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCZaVTyJINmdGy\|IHHmeIVzKDd{IHjyd{whUUN3ME2wMlA2OiEQvF2=	NYjhTGplOTV4MUW1NVI>
PC3 cell	NYPNW\|ltWHKxbHnm[ZJifGmxbjDhd5NigQ>?	MVG3NkBp	NEfhcHRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDh[pRmeiB5MjDodpMtKEmFNUC9NE4xODl2IN88US=>	M4frVVE2PjF3NUGy
MDA-MB-231 cell	MV\Qdo9tcW[ncnH0bY9vKGG\|c3H5	NVvsPFBJPzJiaB?=	MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[W[2ZYKgO\|IhcHK\|LDDJR\|UxRTBwMEGyJO69VQ>?	MkPFNVU3OTV3MUK=
M07ep210 cell	NYTVO\|RnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MWm0PEBp	MXXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNNFdmeDJzMDDj[YxteyCjZoTldkA1QCCqcoOgZpkhYzOKXYTofY1q\GmwZTD1dJRic2ViYYPzZZktKEmFNUC9NE4xPyCwTR?=	MYOxO\|k2PjB6MB?=
K562 cell	M4e3O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MYO0PEBp	MoXtS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT\|U3OiClZXzsd{Bi\nSncjC0PEBpenNiYomgX\|NJZXSqeX3p[Ilv\SC3cIThb4Uh[XO\|YYmsJGlEPTB;MD6wNFEh\|ryP	NFLhclQyPzl3NkC4NC=>
M07e cell	NHztR5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NVvQdohmPDhiaB?=	MULHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNNFdmKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDbN2hefGi7bXnkbY5mKHWydHHr[UBie3OjeTygTWM2OD1yLkCwNVIh\|ryP	MlPINVc6PTZyOEC=
K562 cell	NWL4c2w6S3m2b4TvfIlkcXS7IHHzd4F6	M4ruRlczKGh?	M1fNXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHdUXC16IILlZYdmdnRiYnHz[YQhVVSWIHHzd4F6NCCLQ{WwQVEzNjh\|IN88US=>	NVftXJliOjJ{MUe4O\|c>
U937 cell	NFrPU5hEgXSxdH;4bYNqfHliYYPzZZk>	NFHNTGM4OiCq	MoPBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVk{PyClZXzsd{Bi\nSncjC3NkBpenNiYomgW3NVNThicnXh[4VvfCCkYYPl[EBOXFRiYYPzZZktKEmFNUC9NVMvPjNizszN	NIPSOHYzOjJzN{i3Oy=>
K562 cell	Ml\LVJJwdGmoZYLheIlwdiCjc4PhfS=>	M1mzfVczKGh?	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOFS{igZZN{[XluIFnDOVA:OC55IH7N	MW[yN\|UzOTB{MB?=
MDA-MB-435S cell	NV31SWxLWHKxbHnm[ZJifGmxbjDhd5NigQ>?	M2rDVVczKGh?	MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk01OzWVIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9N{46KM7:TR?=	NV3UTIJpOjN3MkGwNlA>
NCI-H460 cell	MlPNVJJwdGmoZYLheIlwdiCjc4PhfS=>	M4Hhc\|czKGh?	NFPDVmdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPDZyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9PE46QSEQvF2=	MmfNNlM2OjFyMkC=
NCI-H23 cell	M4KwNnBzd2yrZnXyZZRqd25iYYPzZZk>	M4LwXFczKGh?	MlnxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFI{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;Mj6yO{DPxE1?	M2TMeFI{PTJzMEKw
A549 cell	M4XVWHBzd2yrZnXyZZRqd25iYYPzZZk>	MmfaO\|IhcA>?	MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yOi54NjFOwG0>	MmfyNlM2OjFyMkC=
T47D cell	MmLpVJJwdGmoZYLheIlwdiCjc4PhfS=>	MVS3NkBp	MoLzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCWNEfEJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC57IN88US=>	NWrROY9bOjN3MkGwNlA>
HCT116 cell	MkLNVJJwdGmoZYLheIlwdiCjc4PhfS=>	MlfXO\|IhcA>?	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTJwMzFOwG0>	MlW5NlM2OjFyMkC=
MCF7 cells	NYHuT4JCWHKxbHnm[ZJifGmxbjDhd5NigQ>?	Mmm0O\|IhcA>?	NUDjPHJnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;Mj61O{DPxE1?	MVqyN\|UzOTB{MB?=
RXF 393NL cell	NVniWmt3S3m2b4TvfIlkcXS7IHHzd4F6	MV60JIRigXN?	MV\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDSXGYhOzl\|TlygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoctKEmFNUC9NlEvPyCwTR?=	M3v0XVI{OjV\|MEe0
PRXF DU145 cell	M3zxb2N6fG:2b4jpZ4l1gSCjc4PhfS=>	NY[5S\|hPPCCmYYnz	NYTOfY1vS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWFK[RjDEWVE1PSClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzygTWM2OD1yLkC2NlMh\|ryP	MmXlNlMzPTNyN{S=
LXFA 983L cell	NX;QV4hxS3m2b4TvfIlkcXS7IHHzd4F6	MWS0JIRigXN?	NHfGZolEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNYE[DIEm4N2wh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmduIFnDOVA:PTZwNTDuUS=>	MlHQNlMzPTNyN{S=
GXF251L cell	NWTVVJVES3m2b4TvfIlkcXS7IHHzd4F6	M3XkVlQh\GG7cx?=	M2TrdGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGdZTjJ3MVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoctKEmFNUC9Nk4zPSEQvF2=	MorRNlMzPTNyN{S=
CXF 1103L cell	MXjDfZRwfG:6aXPpeJkh[XO\|YYm=	M1jBWVQh\GG7cx?=	MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDXGYhOTFyM1ygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoctKEmFNUC9OE4{PiEQvF2=	MmD6NlMzPTNyN{S=
PAXF 1657L cell	MUDDfZRwfG:6aXPpeJkh[XO\|YYm=	MVK0JIRigXN?	MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQRXhHKDF4NUfMJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNCCLQ{WwQVAvOTJzIN88US=>	MYKyN\|I2OzB5NB?=
NCI-H1648 cell	NHPNNnhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4DsS2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlQ5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yMkCxNUDPxE1?	NIfvNJpUSU6JRWK=
NCI-H1838 cell	NVzZPHBjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGfvW4VKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVg{QCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwM{C3N\|Mh\|ryP	NHXzNllUSU6JRWK=
NCI-H2126 cell	MkDCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NE\FSIZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlEzPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwOEe1OVIh\|ryP	M33SfnNCVkeHUh?=
NCI-H2141 cell	NF\SXHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M37tUGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNVQyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjRwN{e1OEDPxE1?	NXPzfnZOW0GQR1XS
NCI-H2107 cell	NGfiVHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MX\Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkGwO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ{NjR6NEeg{txO	NIW3fWZUSU6JRWK=
NCI-H747 cell	M1HZO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGHwUW5KdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO\|Q4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yOEO2NkDPxE1?	NETTdIRUSU6JRWK=
NCI-H720 cell	M3TJXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mmm2TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEeyNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIxNjJ5M{Og{txO	Ml2xV2FPT0WU
NKM-1 cell	NYX5[2lvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXHJcohq[mm2aX;uJI9nKGi3bXHuJG5MVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1zLkOwPFU6KM7:TR?=	NEjROoNUSU6JRWK=
NMC-G1 cell	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVnJcohq[mm2aX;uJI9nKGi3bXHuJG5OSy2JMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6xNVYxPiEQvF2=	NUPiXoRpW0GQR1XS
NTERA-S-cl-D1 cell	MkPZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWH0SZRjUW6qaXLpeIlwdiCxZjDoeY1idiCQVFXSRU1UNWOuLVSxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlEzOjh\|IN88US=>	Mm\RV2FPT0WU
OCI-AML2 cell	NX3PVVRXT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVzJcohq[mm2aX;uJI9nKGi3bXHuJG9EUS2DTVyyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME21Mlg3OTV2IN88US=>	MV3TRW5ITVJ?
OCUB-M cell	MoX0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlfvTY5pcWKrdHnvckBw\iCqdX3hckBQS1WELV2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUGuNFQ1OTJizszN	MV7TRW5ITVJ?
OPM-2 cell	M1LrfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NV7kO\|JvUW6qaXLpeIlwdiCxZjDoeY1idiCRUF2tNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9OE4zPzZ6NTFOwG0>	MUTTRW5ITVJ?
OS-RC-2 cell	NV7QbWNxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXLJcohq[mm2aX;uJI9nKGi3bXHuJG9UNVKFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNFIxOyEQvF2=	M4rrVXNCVkeHUh?=
ONS-76 cell	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVLJcohq[mm2aX;uJI9nKGi3bXHuJG9PWy15NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD60Nlk2OSEQvF2=	MX3TRW5ITVJ?
OVCAR-4 cell	NUKzcWtuT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVHJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuN\|c1OzNizszN	MkKyV2FPT0WU
NCI-H446 cell	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNES2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlYzPzZizszN	NUn4OWFoW0GQR1XS
NCI-H510A cell	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEPsPXNKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVExSSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OTlwM{m3N{DPxE1?	MVHTRW5ITVJ?
PF-382 cell	MmnYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWHJcohq[mm2aX;uJI9nKGi3bXHuJHBHNTN6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6xO\|Y4QCEQvF2=	MUjTRW5ITVJ?
NCI-H64 cell	MoTYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MV\Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUK5MlYzPTNizszN	MYDTRW5ITVJ?
PSN1 cell	MkniS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3;rSGlvcGmkaYTpc44hd2ZiaIXtZY4hWFOQMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6wOFQ4PCEQvF2=	MXnTRW5ITVJ?
QIMR-WIL cell	NYj5bldXT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1jHTmlvcGmkaYTpc44hd2ZiaIXtZY4hWUmPUj3XTWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvPzB4Mkmg{txO	Mn\LV2FPT0WU
RL95-2 cell	M3;GXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXXJcohq[mm2aX;uJI9nKGi3bXHuJHJNQTVvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6xNFM5KM7:TR?=	M130O3NCVkeHUh?=
RCC10RGB cell	MkHLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWfpT21wUW6qaXLpeIlwdiCxZjDoeY1idiCUQ1OxNHJISiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OC52OUGxJO69VQ>?	M3\EenNCVkeHUh?=
RKO cell	NE[5V21Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVjJcohq[mm2aX;uJI9nKGi3bXHuJHJMVyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OC53Mkm2OkDPxE1?	MVfTRW5ITVJ?
NCI-SNU-16 cell	NXTpdFF1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mn;5TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvU17VMVE3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF05NjV4MUK4JO69VQ>?	NIXZPZBUSU6JRWK=
RPMI-6666 cell	NHHidpNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGLnZWtKdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtOlY3PiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:Py5{N{C2O{DPxE1?	MXvTRW5ITVJ?
NEC8 cell	NFL6O4lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmnCTY5pcWKrdHnvckBw\iCqdX3hckBPTUN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD12ND6zN\|Yh\|ryP	NUnpcJpqW0GQR1XS
RS4-11 cell	M3rCUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2HPZWlvcGmkaYTpc44hd2ZiaIXtZY4hWlN2LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME23MlY2Pzh5IN88US=>	NH\vOJBUSU6JRWK=
RXF393 cell	Ml3mS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkPQTY5pcWKrdHnvckBw\iCqdX3hckBTYEZ\|OUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNFI{PTdizszN	NUPPPZJqW0GQR1XS
Raji cell	NGDhSIVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4H6ZWlvcGmkaYTpc44hd2ZiaIXtZY4hWmGsaTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MUOuO\|Q6PyEQvF2=	NYLzTJBIW0GQR1XS
NOS-1 cell	MojRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmqxTY5pcWKrdHnvckBw\iCqdX3hckBPV1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6wNFYyOjlizszN	M3PRRnNCVkeHUh?=
SBC-1 cell	NWTEUlluT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHHWZ3NKdmirYnn0bY9vKG:oIHj1cYFvKFOEQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2xMlU4QTh2IN88US=>	M3zRVHNCVkeHUh?=
SF126 cell	NX32e2IxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGS2b25KdmirYnn0bY9vKG:oIHj1cYFvKFOIMUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlM2PDFizszN	MXLTRW5ITVJ?
SF539 cell	Mn\5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M33RNmlvcGmkaYTpc44hd2ZiaIXtZY4hW0Z3M{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUGzMlg2PTdizszN	NX;kVFhQW0GQR1XS
SH-4 cell	NXm2TmxRT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXf6Ro1xUW6qaXLpeIlwdiCxZjDoeY1idiCVSD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlE5PDF\|IN88US=>	NVi4XFNsW0GQR1XS
OMC-1 cell	M3HGR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGXWTWpKdmirYnn0bY9vKG:oIHj1cYFvKE:PQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2yO{4yPDJ{IN88US=>	MUHTRW5ITVJ?
SIG-M5 cell	M{LNb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkP0TY5pcWKrdHnvckBw\iCqdX3hckBUUUdvTUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUmuNFI1QTNizszN	MkTFV2FPT0WU
SJSA-1 cell	M4ns[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M37GSmlvcGmkaYTpc44hd2ZiaIXtZY4hW0qVQT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME24MlczQDB3IN88US=>	M4jaTnNCVkeHUh?=
SK-LMS-1 cell	MmjYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHnKenNKdmirYnn0bY9vKG:oIHj1cYFvKFONLVzNV{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0{NjFzOEi2JO69VQ>?	NIXqN5VUSU6JRWK=
SK-NEP-1 cell	NFfGPW5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M{DMNWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTlXQMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVgvQDlzNUWg{txO	NX7x[FdVW0GQR1XS
SKM-1 cell	MmLCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHW1W\|RKdmirYnn0bY9vKG:oIHj1cYFvKFONTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME25MlAyPzN2IN88US=>	M3OyRXNCVkeHUh?=
SK-PN-DW cell	NFHVW4dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3zlfmlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvUF6tSHch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVM3NjF7NEOg{txO	NXTOV4tnW0GQR1XS
SK-UT-1 cell	NHLn[ldIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHjoZ2VKdmirYnn0bY9vKG:oIHj1cYFvKFONLWXUMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVIvOTZ4OUOg{txO	M3vMO3NCVkeHUh?=
SNB75 cell	M3HteGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3SxUGlvcGmkaYTpc44hd2ZiaIXtZY4hW06EN{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNFQ1OzVizszN	MlvzV2FPT0WU
REH cell	Mly5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVnJcohq[mm2aX;uJI9nKGi3bXHuJHJGUCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OjBwNkO1O{DPxE1?	NXnVd3BLW0GQR1XS
SNU-C2B cell	Moq0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{\tRmlvcGmkaYTpc44hd2ZiaIXtZY4hW06XLVOyRkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NU4{ODV6OTFOwG0>	M1TVXnNCVkeHUh?=
RPMI-8866 cell	NV7HdXVkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MljrTY5pcWKrdHnvckBw\iCqdX3hckBTWE2LLUi4OlYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVE4NjR2NUWg{txO	MVLTRW5ITVJ?
SW872 cell	M4GxRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXzJcohq[mm2aX;uJI9nKGi3bXHuJHNYQDd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkC0NVYyKM7:TR?=	NF7RdZBUSU6JRWK=
SW962 cell	NG[5UnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVHJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTZ{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkGxNlkzKM7:TR?=	M2jGW3NCVkeHUh?=
SF268 cell	M3vGZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NX7iXXJDUW6qaXLpeIlwdiCxZjDoeY1idiCVRkK2PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4yPzRyNDFOwG0>	M4jORnNCVkeHUh?=
TE-1 cell	Mlj1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mkj1TY5pcWKrdHnvckBw\iCqdX3hckBVTS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkGwOVQh\|ryP	NYnsZolQW0GQR1XS
8-MG-BA cell	MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVHSXnBpUW6qaXLpeIlwdiCxZjDoeY1idiB6LV3HMWJCKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjF3NEW4JO69VQ>?	M1zZXHNCVkeHUh?=
A101D cell	Mk\OS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlzaTY5pcWKrdHnvckBw\iCqdX3hckBCOTBzRDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MT6wN\|A1OyEQvF2=	M3vXUnNCVkeHUh?=
A253 cell	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{DMb2lvcGmkaYTpc44hd2ZiaIXtZY4hSTJ3MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;Mz63N\|I1PiEQvF2=	MWjTRW5ITVJ?
A3-KAW cell	MnjnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Ml\mTY5pcWKrdHnvckBw\iCqdX3hckBCOy2NQWegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuPVg1PTJizszN	Mki3V2FPT0WU
A4-Fuk cell	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Ml:xTY5pcWKrdHnvckBw\iCqdX3hckBCPC2IdXugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUO4MlExODlizszN	MmXGV2FPT0WU
A388 cell	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWHJcohq[mm2aX;uJI9nKGi3bXHuJGE{QDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTBwMEWwPVUh\|ryP	MW\TRW5ITVJ?
ACN cell	NVfqW3EzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1H2RmlvcGmkaYTpc44hd2ZiaIXtZY4hSUOQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1zLkiyNlUzKM7:TR?=	M{fqd3NCVkeHUh?=
A704 cell	NVLycZg1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlzTTY5pcWKrdHnvckBw\iCqdX3hckBCPzB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkCxOFkyKM7:TR?=	NYLLdIFEW0GQR1XS
ALL-PO cell	NH7aSlBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MojNTY5pcWKrdHnvckBw\iCqdX3hckBCVExvUF:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUGwMlc6OzhizszN	NGjwdmJUSU6JRWK=
ARH-77 cell	M2L3TGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWrJcohq[mm2aX;uJI9nKGi3bXHuJGFTUC15NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;Mz60OlkyPSEQvF2=	M331b3NCVkeHUh?=
SR cell	Mm\1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Ml7HTY5pcWKrdHnvckBw\iCqdX3hckBUWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:PC52OUm1OEDPxE1?	M3nYUHNCVkeHUh?=
BB65-RCC cell	M{nteGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmHUTY5pcWKrdHnvckBw\iCqdX3hckBDSjZ3LWLDR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xQDJ{NzFOwG0>	MUDTRW5ITVJ?
BB49-HNC cell	NIf1do9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MknUTY5pcWKrdHnvckBw\iCqdX3hckBDSjR7LVjOR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4{QDV7OTFOwG0>	MmHoV2FPT0WU
BC-1 cell	MoXjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnTUTY5pcWKrdHnvckBw\iCqdX3hckBDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1{OD62OVEh\|ryP	NEPUbJZUSU6JRWK=
BC-3 cell	NVHENGIzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXjJcohq[mm2aX;uJI9nKGi3bXHuJGJENTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTF{LkGxN\|gh\|ryP	MYDTRW5ITVJ?
BL-41 cell	NUDQbmdOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NV7RT5N5UW6qaXLpeIlwdiCxZjDoeY1idiCETD20NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4zQTF{MzFOwG0>	MnrsV2FPT0WU
BL-70 cell	NESzcmlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUfJcohq[mm2aX;uJI9nKGi3bXHuJGJNNTdyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkCwNFAxODh{MUig{txO	NUP2UHVZW0GQR1XS
SW684 cell	MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3XX[WlvcGmkaYTpc44hd2ZiaIXtZY4hW1d4OESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuN\|Q6QCEQvF2=	MmPDV2FPT0WU
BOKU cell	M{i4eWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUnJcohq[mm2aX;uJI9nKGi3bXHuJGJQU1ViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTBwNEmxN\|Mh\|ryP	NV;HdHc1W0GQR1XS
SW954 cell	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlzvTY5pcWKrdHnvckBw\iCqdX3hckBUXzl3NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6wNlkzPyEQvF2=	NEiwfJRUSU6JRWK=
C2BBe1 cell	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NH7PNZJKdmirYnn0bY9vKG:oIHj1cYFvKEN{QlLlNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xQDNyODFOwG0>	M4fjU3NCVkeHUh?=
BV-173 cell	NVf3SWpLT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mn\pTY5pcWKrdHnvckBw\iCqdX3hckBDXi1zN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNFAxODByMUC5JO69VQ>?	M4fEVXNCVkeHUh?=
Becker cell	Mn7nS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NH;zPYJKdmirYnn0bY9vKG:oIHj1cYFvKEKnY3vldkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xOzByMzFOwG0>	NEnEV3hUSU6JRWK=
SW982 cell	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NETMdIpKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlAyOTF3IN88US=>	NVnSV2gzW0GQR1XS
697 cell	NULnbVJqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MmPlTY5pcWKrdHnvckBw\iCqdX3hckA3QTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTBwMUm5PFch\|ryP	MmrNV2FPT0WU
TE-15 cell	M1TtcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVPJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTF3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkCwOVg6OSEQvF2=	NEj5eJBUSU6JRWK=
TE-11 cell	NYLIRY16T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3OzXmlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNFc5PThizszN	NWHofHFZW0GQR1XS
TE-5 cell	NXHNe\|J2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MV;Jcohq[mm2aX;uJI9nKGi3bXHuJHRGNTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTFwN{mxN\|kh\|ryP	MnjkV2FPT0WU
TE-6 cell	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4[2XmlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MT6yNVIzPiEQvF2=	NELufldUSU6JRWK=
TE-9 cell	NWXXVZllT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXK3Xmh2UW6qaXLpeIlwdiCxZjDoeY1idiCWRT25JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlg4PTN{IN88US=>	M{\IVXNCVkeHUh?=
TGBC24TKB cell	Mkm5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYrwV2EyUW6qaXLpeIlwdiCxZjDoeY1idiCWR1LDNlRVU0JiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTBwMES3OlEh\|ryP	MWHTRW5ITVJ?
TGW cell	M{DSPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NEfmWpVKdmirYnn0bY9vKG:oIHj1cYFvKFSJVzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MUGuNlgzQCEQvF2=	MkjRV2FPT0WU
TK10 cell	M{G4dGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVjJcohq[mm2aX;uJI9nKGi3bXHuJHRMOTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTBwMEGxO\|Qh\|ryP	MYjTRW5ITVJ?
TGBC1TKB cell	M1fN[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWj0OIdwUW6qaXLpeIlwdiCxZjDoeY1idiCWR1LDNXRMSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OC5yNkG2OEDPxE1?	M1XhXnNCVkeHUh?=
A498 cell	NGHnWZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M{LBZWlvcGmkaYTpc44hd2ZiaIXtZY4hSTR7ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6wO\|I5PCEQvF2=	NUf0NndUW0GQR1XS
UACC-257 cell	MkXLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEPEcZhKdmirYnn0bY9vKG:oIHj1cYFvKFWDQ1OtNlU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0yOi57MUm4JO69VQ>?	M1Lv[3NCVkeHUh?=
U-87-MG cell	NGX5eWFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4HYO2lvcGmkaYTpc44hd2ZiaIXtZY4hXS16Nz3NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9N\|AvPzZ4IN88US=>	NEjrSm9USU6JRWK=
BB30-HNC cell	NXTLfoJXT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWrJcohq[mm2aX;uJI9nKGi3bXHuJGJDOzBvSF7DJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlA2PDN5IN88US=>	NIXFPWdUSU6JRWK=
no-10 cell	M3r1Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXjxc2NXUW6qaXLpeIlwdiCxZjDoeY1idiCwbz2xNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4{OTl\|MTFOwG0>	MlXiV2FPT0WU
CAS-1 cell	M2fROWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NG\rSIZKdmirYnn0bY9vKG:oIHj1cYFvKEODUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2xMlQxQTl{IN88US=>	MnHsV2FPT0WU
CGTH-W-1 cell	NV\RcFE3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYPJcohq[mm2aX;uJI9nKGi3bXHuJGNIXEhvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlA{PTR6IN88US=>	MV7TRW5ITVJ?
TE-10 cell	NUTvcFBQT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVXNVWJ6UW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xPjN3NzFOwG0>	NYjBT3cxW0GQR1XS
COLO-684 cell	MlO3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVHJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNki0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME20Ok4zOjV6IN88US=>	NI\PTVhUSU6JRWK=
TE-12 cell	NHv4R29Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYDJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkCxPFYyKM7:TR?=	NGr6SYNUSU6JRWK=
COR-L279 cell	M4Tk[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXzJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMke5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME20NE4zQDV{IN88US=>	Mm\TV2FPT0WU
TE-8 cell	NVO0N3BiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3jDSWlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6wNVU4PiEQvF2=	NH7JRWRUSU6JRWK=
CP66-MEL cell	M1fieWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mmf2TY5pcWKrdHnvckBw\iCqdX3hckBEWDZ4LV3FUEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4yQTV\|MTFOwG0>	MXPTRW5ITVJ?
CTV-1 cell	MofUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGNVXi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkCwNFA1ODN4IN88US=>	NWjXbmlPW0GQR1XS
VA-ES-BJ cell	NFrqS\|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2XJVWlvcGmkaYTpc44hd2ZiaIXtZY4hXkFvRWOtRmoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvODN7MEKg{txO	MXPTRW5ITVJ?
D-263MG cell	MmjFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MoTnTY5pcWKrdHnvckBw\iCqdX3hckBFNTJ4M13HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlM3OjJ2IN88US=>	MY\TRW5ITVJ?
D-336MG cell	MnnvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXHHVIVnUW6qaXLpeIlwdiCxZjDoeY1idiCGLUOzOm1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjByNkK5PEDPxE1?	NVixfHJMW0GQR1XS
D-502MG cell	NYLkRnVKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXvJcohq[mm2aX;uJI9nKGi3bXHuJGQuPTB{TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUGuNlM{PzZizszN	NYH0cYN5W0GQR1XS
DJM-1 cell	NU[0WpV3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVXJcohq[mm2aX;uJI9nKGi3bXHuJGRLVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD14LkS4OVU5KM7:TR?=	MkCzV2FPT0WU
no-11 cell	NFnHUo5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NInoVm9KdmirYnn0bY9vKG:oIHj1cYFvKG6xLUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlUxOjJ6IN88US=>	NHXhW3NUSU6JRWK=
DMS-153 cell	NIn1c\|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoD6TY5pcWKrdHnvckBw\iCqdX3hckBFVVNvMUWzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2xOE4xODJ6IN88US=>	NGPpdpFUSU6JRWK=
DSH1 cell	NXuwUGF1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXPJcohq[mm2aX;uJI9nKGi3bXHuJGRUUDFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTBwMkSwNFEh\|ryP	MlXoV2FPT0WU
DU-4475 cell	M33sUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVTSWHVWUW6qaXLpeIlwdiCxZjDoeY1idiCGVT20OFc2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF05NjJzNkWyJO69VQ>?	MoqxV2FPT0WU
EB-3 cell	MmnaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGf3R4xKdmirYnn0bY9vKG:oIHj1cYFvKEWELUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUO0MlMyOThizszN	MlL0V2FPT0WU
EHEB cell	NE[1dJJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXP5cHhoUW6qaXLpeIlwdiCxZjDoeY1idiCHSFXCJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2xNE4xPjV4IN88US=>	NYDFS3F3W0GQR1XS
COLO-829 cell	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmjlTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUiyPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4yOjJzMzFOwG0>	M{Dae3NCVkeHUh?=
CP67-MEL cell	NHLQcFNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mo\lTY5pcWKrdHnvckBw\iCqdX3hckBEWDZ5LV3FUEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4zODR6ODFOwG0>	NFrhNpVUSU6JRWK=
ES8 cell	NV23XmFkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MoG3TY5pcWKrdHnvckBw\iCqdX3hckBGWzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTN{LkGyOVIh\|ryP	NW\KWVNSW0GQR1XS
EVSA-T cell	Mn7aS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVvCRlJKUW6qaXLpeIlwdiCxZjDoeY1idiCHVmPBMXQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVkvOjd5OUOg{txO	NVvvZnN{W0GQR1XS
ES4 cell	Ml;LS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NV;kRZkyUW6qaXLpeIlwdiCxZjDoeY1idiCHU{SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUGuNFUyPDVizszN	NF7PdYtUSU6JRWK=
ETK-1 cell	NIPUbGdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVHJcohq[mm2aX;uJI9nKGi3bXHuJGVVUy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkCyPFMzKM7:TR?=	MYjTRW5ITVJ?
ES6 cell	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXH6R25vUW6qaXLpeIlwdiCxZjDoeY1idiCHU{[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNFMyQTNizszN	NXvDcmdTW0GQR1XS
EW-24 cell	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWnJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTJ2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLke4NVY2KM7:TR?=	MYrTRW5ITVJ?
EoL-1-cell cell	NI[yemtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnS1TY5pcWKrdHnvckBw\iCqdX3hckBGd0xvMT3j[YxtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjByMECxN\|A6KM7:TR?=	M2PxV3NCVkeHUh?=
Calu-6 cell	Mo\TS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYLJcohq[mm2aX;uJI9nKGi3bXHuJGNidHVvNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;Mz6wOVc1OSEQvF2=	NXHMOVhQW0GQR1XS
GAK cell	NF3DNpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXL2ZnpIUW6qaXLpeIlwdiCxZjDoeY1idiCJQVugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUOxMlI3QDZizszN	Mo[5V2FPT0WU
D-247MG cell	M4r4cmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1HBXGlvcGmkaYTpc44hd2ZiaIXtZY4hTC1{NEfNS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9Ok4yOjVzOTFOwG0>	NGniUHBUSU6JRWK=
GB-1 cell	NVvXV5R4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MmTBTY5pcWKrdHnvckBw\iCqdX3hckBISi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkCyNVU4KM7:TR?=	NGfEeZJUSU6JRWK=
GI-ME-N cell	MkW4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{j3NGlvcGmkaYTpc44hd2ZiaIXtZY4hT0lvTVWtUkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xPjFzODFOwG0>	M4iweHNCVkeHUh?=
GCIY cell	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mn\XTY5pcWKrdHnvckBw\iCqdX3hckBIS0m\IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkC5OlU3KM7:TR?=	NGjDeVNUSU6JRWK=
GT3TKB cell	NYjnSoxTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Ml\sTY5pcWKrdHnvckBw\iCqdX3hckBIXDOWS1KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUmuN\|U2PDZizszN	MUjTRW5ITVJ?
HC-1 cell	NF3TbXZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3z4WGlvcGmkaYTpc44hd2ZiaIXtZY4hUENvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MkSuOVU2OSEQvF2=	MVPTRW5ITVJ?
HAL-01 cell	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGP5OIZKdmirYnn0bY9vKG:oIHj1cYFvKEiDTD2wNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NVkvPzV2MzFOwG0>	NITCcZZUSU6JRWK=
HCC1187 cell	NHPPZphIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MofFTY5pcWKrdHnvckBw\iCqdX3hckBJS0NzMUi3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2zOU45ODV{IN88US=>	MnnoV2FPT0WU
DEL cell	NFvDWW9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYW1dWdvUW6qaXLpeIlwdiCxZjDoeY1idiCGRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUSxMlkxQDZizszN	MmHjV2FPT0WU
HCC1599 cell	M4jTV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Ml7wTY5pcWKrdHnvckBw\iCqdX3hckBJS0NzNUm5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2zNk4{OzJ3IN88US=>	MmLjV2FPT0WU
DOHH-2 cell	NWDI[ZZwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NH;xeWxKdmirYnn0bY9vKG:oIHj1cYFvKESRSFitNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xOTdzOTFOwG0>	NGT6blNUSU6JRWK=
HCC2157 cell	M2XST2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGhESzJzNUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUO3Mlk6PDZizszN	MmrYV2FPT0WU
HCE-4 cell	M1f1V2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVXJcohq[mm2aX;uJI9nKGi3bXHuJGhETS12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkK2OFM6KM7:TR?=	NWjYUnM2W0GQR1XS
HCE-T cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWfJcohq[mm2aX;uJI9nKGi3bXHuJGhETS2WIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1zLkW2O\|E1KM7:TR?=	MXXTRW5ITVJ?
HEL cell	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXHJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OTBwNEe3OkDPxE1?	M3G3NnNCVkeHUh?=
EM-2 cell	MmO4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NInJSJlKdmirYnn0bY9vKG:oIHj1cYFvKEWPLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNFAxODBzMEe4JO69VQ>?	M12wXXNCVkeHUh?=
HT-144 cell	NXHIOW5ET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MoToTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zNESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuOVM3ODlizszN	MUPTRW5ITVJ?
EW-16 cell	NWHK[45ZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGXhZWhKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlc3OTd6IN88US=>	MV;TRW5ITVJ?
IA-LM cell	NWDQV5E{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M2mySGlvcGmkaYTpc44hd2ZiaIXtZY4hUUFvTF2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUGyMlQ1PDVizszN	M4r5WXNCVkeHUh?=
IST-MEL1 cell	NIe0RoJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlzWTY5pcWKrdHnvckBw\iCqdX3hckBKW1RvTVXMNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4yOzR3IN88US=>	MX7TRW5ITVJ?
IST-MES1 cell	NHfrR\|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1;sbmlvcGmkaYTpc44hd2ZiaIXtZY4hUVOWLV3FV\|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVAvODh3NUKg{txO	M4D1PXNCVkeHUh?=
GI-1 cell	NFe0WJdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2rNd2lvcGmkaYTpc44hd2ZiaIXtZY4hT0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MT6zOlIzKM7:TR?=	NEnMSVRUSU6JRWK=
IST-SL2 cell	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUnJcohq[mm2aX;uJI9nKGi3bXHuJGlUXC2VTEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuOVA{ODJizszN	M1zvcHNCVkeHUh?=
JVM-2 cell	NYXvblI6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1;vUWlvcGmkaYTpc44hd2ZiaIXtZY4hUl[PLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUKuN\|YzQDRizszN	NXztNXlHW0GQR1XS
JVM-3 cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFW5RWZKdmirYnn0bY9vKG:oIHj1cYFvKEqYTT2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2zO{4zOzN6IN88US=>	NWCwVWlrW0GQR1XS
KALS-1 cell	NGnaW2dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkTnTY5pcWKrdHnvckBw\iCqdX3hckBMSUyVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNFk1QSEQvF2=	NG\SPJhUSU6JRWK=
KARPAS-422 cell	M1nTb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWjVOJNFUW6qaXLpeIlwdiCxZjDoeY1idiCNQWLQRXMuPDJ{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkOzPVk4KM7:TR?=	NHnUVWJUSU6JRWK=
JiyoyeP-2003 cell	NVfVOFBHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFTPOYFKdmirYnn0bY9vKG:oIHj1cYFvKEqreX;5[XAuOjByMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MT63N\|Q3PiEQvF2=	NXy0dI46W0GQR1XS
KARPAS-45 cell	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NI[4N\|hKdmirYnn0bY9vKG:oIHj1cYFvKEuDUmDBV{01PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:Py53MU[3NUDPxE1?	NHrzbmtUSU6JRWK=
KGN cell	NX;PZ5lPT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVjJcohq[mm2aX;uJI9nKGi3bXHuJGtIViClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OC5yMUm0NkDPxE1?	NVnZUJpXW0GQR1XS
KLE cell	NVqycnhiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVLtfY5XUW6qaXLpeIlwdiCxZjDoeY1idiCNTFWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNVE{OTdizszN	MmW3V2FPT0WU
KNS-42 cell	NUSyTGdVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVjJcohq[mm2aX;uJI9nKGi3bXHuJGtPWy12MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MT6yOFQyOiEQvF2=	NWfhSlBrW0GQR1XS
KNS-81-FD cell	NGPwR5NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHWwW3JKdmirYnn0bY9vKG:oIHj1cYFvKEuQUz24NU1HTCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OjNwMUS2JO69VQ>?	MYPTRW5ITVJ?
KP-N-YS cell	NEPtPHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWnheIZUUW6qaXLpeIlwdiCxZjDoeY1idiCNUD3OMXlUKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0yOi57MkizJO69VQ>?	NX7YSZBJW0GQR1XS
HOP-62 cell	MnftS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NI[3cWxKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xOTh\|NDFOwG0>	NXfXZXBJW0GQR1XS
KURAMOCHI cell	M{fRTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M37QOmlvcGmkaYTpc44hd2ZiaIXtZY4hU1WUQV3PR2hKKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjB\|NEi3JO69VQ>?	NEnqZXZUSU6JRWK=
HUTU-80 cell	NHTUSY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVT3d5NYUW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjNzNEKg{txO	NXfHZXZ6W0GQR1XS
LAMA-84 cell	M1rJOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWO2XHcyUW6qaXLpeIlwdiCxZjDoeY1idiCOQV3BMVg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjByMECwN\|IxPyEQvF2=	NIHLUWtUSU6JRWK=
LB1047-RCC cell	NGrVUIRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml3ETY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjByOUi4O{DPxE1?	MoDLV2FPT0WU
LB2518-MEL cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NInS[nJKdmirYnn0bY9vKG:oIHj1cYFvKEyEMkWxPE1OTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTBwMUSxOlIh\|ryP	NV3GR49[W0GQR1XS
LB373-MEL-D cell	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYXJcohq[mm2aX;uJI9nKGi3bXHuJGxDOzd\|LV3FUE1FKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjh{NUC4JO69VQ>?	NGDkeFBUSU6JRWK=
LB771-HNC cell	NYHOdXh4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWPJcohq[mm2aX;uJI9nKGi3bXHuJGxDPzdzLVjOR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9Nk42PzV3MTFOwG0>	NEDTdGxUSU6JRWK=
LB996-RCC cell	MlzuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1i3XmlvcGmkaYTpc44hd2ZiaIXtZY4hVEJ7OU[tVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjByOUmxNkDPxE1?	NXWyV4xiW0GQR1XS
LC-2-ad cell	MmK4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWXhXnVGUW6qaXLpeIlwdiCxZjDoeY1idiCOQz2yMYFlKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjB{NUi2JO69VQ>?	NUK4OnV3W0GQR1XS
J-RT3-T3-5 cell	MlT2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4LkcWlvcGmkaYTpc44hd2ZiaIXtZY4hUi2UVEOtWFMuPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:QC57NkWyPUDPxE1?	MXXTRW5ITVJ?
LP-1 cell	NXLY[GRWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1PrXmlvcGmkaYTpc44hd2ZiaIXtZY4hVFBvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;Nz61OFc5OiEQvF2=	M2fPUnNCVkeHUh?=
K-562 cell	NHr6SmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYDJcohq[mm2aX;uJI9nKGi3bXHuJGsuPTZ{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmuTWM2OD1yLkCwNFAxODJ4NU[g{txO	M4[0NnNCVkeHUh?=
LS-123 cell	M4fqeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYLJcohq[mm2aX;uJI9nKGi3bXHuJGxUNTF{MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6xOFA3PCEQvF2=	Mn;oV2FPT0WU
K5 cell	NYnKT4tST3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXnJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjF4NEi5JO69VQ>?	NGH3O2dUSU6JRWK=
LS-411N cell	M3ThXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NILSV5JKdmirYnn0bY9vKG:oIHj1cYFvKEyVLUSxNW4h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigS6LQ{WwQVQ5NjR5NEig{txO	NXLX[2JvW0GQR1XS
KG-1 cell	M{Hpd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWXRRY1JUW6qaXLpeIlwdiCxZjDoeY1idiCNRz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME20MlYxQDR3IN88US=>	MoPpV2FPT0WU
KINGS-1 cell	MnuyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWTJcohq[mm2aX;uJI9nKGi3bXHuJGtKVkeVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNVY3PjZizszN	NHvNfGRUSU6JRWK=
LXF-289 cell	NHj6[mhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mkn1TY5pcWKrdHnvckBw\iCqdX3hckBNYEZvMki5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlA{QTV4IN88US=>	MlTCV2FPT0WU
MC116 cell	MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4rzZmlvcGmkaYTpc44hd2ZiaIXtZY4hVUNzMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNVE1OSEQvF2=	MVjTRW5ITVJ?
KS-1 cell	M3\6[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVzJcohq[mm2aX;uJI9nKGi3bXHuJGtUNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTBwMEK3N{DPxE1?	M2HHdnNCVkeHUh?=
KU812 cell	M4HRfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MoXKTY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MD6xNVg5OyEQvF2=	NF;adoVUSU6JRWK=
MEG-01 cell	NIfLPHdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmfmTY5pcWKrdHnvckBw\iCqdX3hckBOTUdvMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNFAxODB7OEC1JO69VQ>?	MVHTRW5ITVJ?
MFH-ino cell	M3vYZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1:w[WlvcGmkaYTpc44hd2ZiaIXtZY4hVU[KLXnuc{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xPDd{NDFOwG0>	Ml7VV2FPT0WU
L-540 cell	NInEN4ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXHr[WZCUW6qaXLpeIlwdiCxZjDoeY1idiCOLUW0NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NVUvODZ5MTFOwG0>	MXzTRW5ITVJ?
MHH-NB-11 cell	MmeyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEHGdllKdmirYnn0bY9vKG:oIHj1cYFvKE2KSD3ORk0yOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:PDNwMEixPEDPxE1?	NWjxc3hlW0GQR1XS
MMAC-SF cell	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmnFTY5pcWKrdHnvckBw\iCqdX3hckBOVUGFLWPGJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME24Mlc6OzB5IN88US=>	NX32PYVuW0GQR1XS
LB2241-RCC cell	NH7UdlNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkDFTY5pcWKrdHnvckBw\iCqdX3hckBNSjJ{NEGtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF06NjB{MEGyJO69VQ>?	NWLp[ZhSW0GQR1XS
LB831-BLC cell	MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWHJcohq[mm2aX;uJI9nKGi3bXHuJGxDQDNzLVLMR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4xPDZyOTFOwG0>	NEW4W21USU6JRWK=
MOLT-16 cell	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MofUTY5pcWKrdHnvckBw\iCqdX3hckBOV0yWLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2yPU43Ojl{IN88US=>	M4\VT3NCVkeHUh?=
LC-1F cell	NFOzVVNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoLDTY5pcWKrdHnvckBw\iCqdX3hckBNSy1zRjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MkeuN\|I1PSEQvF2=	M2LWTXNCVkeHUh?=
MOLT-4 cell	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NH\adYlKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NlYvPjd3MzFOwG0>	NHvkemFUSU6JRWK=
MZ1-PC cell	M1jL[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmPFTY5pcWKrdHnvckBw\iCqdX3hckBOYjFvUFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNFMyOTlizszN	M2L0ZnNCVkeHUh?=
MONO-MAC-6 cell	M4PS[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mn;ITY5pcWKrdHnvckBw\iCqdX3hckBOV06RLV3BR{03KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF05NjJ5ME[2JO69VQ>?	NYfLfWtuW0GQR1XS
MZ2-MEL cell	NIrEO\|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVTJcohq[mm2aX;uJI9nKGi3bXHuJG1bOi2PRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNlg2OzdizszN	NWnDRZhlW0GQR1XS
MPP-89 cell	NEfZVIhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1PQdGlvcGmkaYTpc44hd2ZiaIXtZY4hVVCSLUi5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlA1ODR7IN88US=>	MUDTRW5ITVJ?
MZ7-mel cell	M{fZXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mki5TY5pcWKrdHnvckBw\iCqdX3hckBOYjdvbXXsJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2wMlQ4QTFzIN88US=>	MYDTRW5ITVJ?
LOXIMVI cell	NWTTOG92T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGxQYEmPVlmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuN\|E2ODNizszN	M3XFdXNCVkeHUh?=
NALM-6 cell	NXGxUItZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NF;zPINKdmirYnn0bY9vKG:oIHj1cYFvKE6DTF2tOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NE4yQTJ7NTFOwG0>	MkjTV2FPT0WU
NB13 cell	M3rsbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NEDDOYlKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUG5MlQ5PzdizszN	MoHiV2FPT0WU
NB5 cell	NVi3cXd2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHjyTmNKdmirYnn0bY9vKG:oIHj1cYFvKE6ENTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MmlEPTB;MT6zPVgzPyEQvF2=	MnW4V2FPT0WU
NB17 cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVTHVYNbUW6qaXLpeIlwdiCxZjDoeY1idiCQQkG3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvUUN3ME2zMlY{QDR5IN88US=>	NH30cJpUSU6JRWK=
NCCIT cell	NV65bXY5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3fCVmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOFSWSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUKuPFY3OTZizszN	MUnTRW5ITVJ?
NB69 cell	NVH6WXI{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NELDUoFKdmirYnn0bY9vKG:oIHj1cYFvKE6ENkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU5KSzVyPUCuNVQ1OzZizszN	MWDTRW5ITVJ?
NCI-H1304 cell	M3T1WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVPmb\|V7UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE{ODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTJ6LkG2Nlgh\|ryP	NHPFTZJUSU6JRWK=
NCI-H1395 cell	MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWLrO2hwUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE{QTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTR{LkCxOlMh\|ryP	M{jMOHNCVkeHUh?=
MHH-PREB-1 cell	MkGzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlewTY5pcWKrdHnvckBw\iCqdX3hckBOUEhvUGLFRk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XlwSVO1NF0xNjd2NE[5JO69VQ>?	NXzlWHZJW0GQR1XS
MLMA cell	NYPtUopYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MU\Jcohq[mm2aX;uJI9nKGi3bXHuJG1NVUFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTBwMUSwN\|Ih\|ryP	NGHWcHRUSU6JRWK=
MN-60 cell	M3XMcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYDTWpZHUW6qaXLpeIlwdiCxZjDoeY1idiCPTj22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9NVUvOTl5OTFOwG0>	NE\pO3RUSU6JRWK=
MV-4-11 cell	M1X4emdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4fJOGlvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NkmFNUC9OE4{PjR3NDFOwG0>	Mk\nV2FPT0WU
NB6 cell	MkLGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlLqTY5pcWKrdHnvckBw\iCqdX3hckBPSjZiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT7JR\|UxRTlwOUKyOVkh\|ryP	NVrwfndxW0GQR1XS
NCI-H1355 cell	NYW1fIZuT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEi2UHRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVM2PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LlnDOVA:OC5zMUCyPEDPxE1?	Mmr0V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416) ; PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. cleaved caspase 3 ; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control. p-FAK/p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive.	23049975 20145167 23721490
Growth inhibition assay	Cell viability; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

In vivo

Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. ^[3]

Protocol

Kinase Assay: ^[1]	- Collapse Kinase autophosphorylation assays: Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research: ^[1]	- Collapse Cell lines: Ba/F3 cell lines Concentrations: ~32 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC) Dosages: 30 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

- Collapse

Solubility (25°C)

In vitro	DMSO	21 mg/mL warmed (41.5 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+dd H2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dasatinib Monohydrate SDF

Molecular Weight	506.02
Formula	C₂₂H₂₈ClN₇O₃S
CAS No.	863127-77-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	BMS-354825 Monohydrate
Smiles	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO.O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04063124	Recruiting	Drug: Dasatinib + Quercetin	Alzheimer Disease	The University of Texas Health Science Center at San Antonio\|Mayo Clinic	February 14 2020	Phase 1\|Phase 2
NCT04155411	Recruiting	Drug: Dasatinib	Dasatinib\|BCR-ABL\|Chronic Myeloid Leukemia	Shenzhen Second People''s Hospital	December 1 2019	Phase 4
NCT04115059	Recruiting	Drug: Dasatinib	Waldenstrom Macroglobulinemia\|DASATINIB	Jorge J. Castillo MD\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute	November 4 2019	Phase 1
NCT03318770	Not yet recruiting	Drug: Dasatinib and blinatumomab	Acute Lymphoblastic Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	December 2018	--
NCT03625388	Recruiting	Drug: Dasatinib	Chronic Myelogenous Leukemia	Hikma Pharmaceuticals LLC	November 5 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the difference between S1021 and S7782?
Answer:
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

Src Signaling Pathway Map

Related Src Products

SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Defactinib (VS-6063) ^New

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.
Bosutinib (SKI-606)

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.
Dasatinib

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
KX2-391 (Tirbanibulin)

KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
PP1

PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
PP2

PP2 (AG 1879, AGL 1879), a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
WH-4-023

WH-4-023 (KIN001-112, KIN112) is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively. Exhibits >300-fold selectivity against p38α and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases.

Choose Your Country or Region

By Signaling Pathways

By product type

Dasatinib Monohydrate